Stay updated with breaking news from Peer Exchange. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Medical experts dissect critical strategies for monitoring for potential adverse events with bispecific antibodies in a comprehensive panel discussion.
Experts discuss optimal utilization of CSCC and BCC staging systems and risk stratification to guide treatment decisions and the appropriate timing for active surveillance vs intervention.
A panel discussion covers considerations within REMS programs aimed at minimizing risks associated with bispecific therapy. NOTE: Not all FDA-approved bispecific antibodies are associated with a REMS protocol.
Providers delve into considerations for continuation of optimal care when patients receiving bispecific therapy transition between care settings.
The panel examine toxicity and morbidity considerations for the use of hedgehog pathway inhibitors in BCC.